Boston Scientific Corporation (BSX) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Boston Scientific Corporation (NYSE:BSX) have earned an average rating of “Buy” from the twenty-one analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation, thirteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $30.91.

A number of equities research analysts have recently commented on the company. Barclays reiterated a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a research report on Wednesday, January 10th. BMO Capital Markets reiterated a “buy” rating and set a $31.00 price objective on shares of Boston Scientific in a research report on Wednesday, November 29th. Needham & Company LLC upgraded Boston Scientific from a “buy” rating to a “strong-buy” rating and increased their price objective for the company from $25.04 to $32.00 in a research report on Friday, December 8th. Oppenheimer reiterated a “hold” rating on shares of Boston Scientific in a research report on Wednesday, November 29th. Finally, Canaccord Genuity cut their price objective on Boston Scientific from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, November 29th.

In other news, SVP Maulik Nanavaty sold 15,568 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $25.38, for a total value of $395,115.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Valley Gold Master Fund L. Sun bought 408,006 shares of Boston Scientific stock in a transaction dated Tuesday, November 28th. The stock was acquired at an average price of $0.45 per share, with a total value of $183,602.70. Insiders sold 177,032 shares of company stock valued at $4,648,733 in the last 90 days. Corporate insiders own 0.74% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Valeo Financial Advisors LLC purchased a new stake in shares of Boston Scientific in the third quarter valued at $138,000. Steward Partners Investment Advisory LLC acquired a new position in shares of Boston Scientific in the third quarter worth $139,000. Cerebellum GP LLC acquired a new position in shares of Boston Scientific in the fourth quarter worth $126,000. Ironwood Investment Counsel LLC acquired a new position in shares of Boston Scientific in the third quarter worth $204,000. Finally, Perkins Capital Management Inc. acquired a new position in shares of Boston Scientific in the third quarter worth $204,000. Institutional investors own 89.84% of the company’s stock.

Boston Scientific (NYSE BSX) traded down $0.26 on Tuesday, reaching $25.92. The company’s stock had a trading volume of 1,322,627 shares, compared to its average volume of 9,707,938. The firm has a market capitalization of $35,593.24, a P/E ratio of 370.71, a price-to-earnings-growth ratio of 1.88 and a beta of 0.81. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50. Boston Scientific has a 12-month low of $23.29 and a 12-month high of $29.93.

Boston Scientific (NYSE:BSX) last released its earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.34. Boston Scientific had a return on equity of 24.04% and a net margin of 1.15%. The firm had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.39 billion. During the same period in the prior year, the firm posted $0.30 earnings per share. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. research analysts predict that Boston Scientific will post 1.37 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/13/boston-scientific-corporation-bsx-given-consensus-recommendation-of-buy-by-brokerages.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply